Evidence map›Paper›PMID 27155490›Full record

ArticleVaccine2016

Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles.

Tinashe B Ruwona, Haiyue Xu, Xu Li, Amber N Taylor, Yan-Chun Shi, Zhengrong Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. International journal of nanomedicine · 2025
    Article
  6. Article
  7. Review
  8. Advances in Vaccine Adjuvants: Nanomaterials and Small Molecules.Handbook of experimental pharmacology · 2024
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Nano alum: A new solution to the new challenge.Human vaccines & immunotherapeutics · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Adjuvants for Coronavirus Vaccines.Frontiers in immunology · 2020
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Tinashe B RuwonaThe University of Texas at Austin, College of Pharmacy, Pharmaceutics Division, Austin, TX, United States.
Haiyue XuThe University of Texas at Austin, College of Pharmacy, Pharmaceutics Division, Austin, TX, United States.
Xu LiThe University of Texas at Austin, College of Pharmacy, Pharmaceutics Division, Austin, TX, United States.
Amber N TaylorThe University of Texas at Austin, College of Pharmacy, Pharmaceutics Division, Austin, TX, United States.
Yan-Chun ShiInner Mongolia Key Laboratory of Molecular Biology, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. Electronic address: Ycshi5388@163.com.
Zhengrong CuiThe University of Texas at Austin, College of Pharmacy, Pharmaceutics Division, Austin, TX, United States; Inner Mongolia Key Laboratory of Molecular Biology, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. Electronic address: Zhengrong.cui@austin.utexas.edu.
Austin College · USInner Mongolia Medical University · CNThe University of Texas at Austin · US

Funding

Topical DNA immunization by modifying the hair follicle cycleR01AI078304 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2008 to 2011
$1.4M
An innovative approach to improve the activity of an aluminum-containing adjuvantR21AI105789 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2013 to 2014
$424k
NIAID NIH HHS R01 AI078304NIAID NIH HHS R21 AI105789
6 · The paper itself

Abstract

Aluminum salts such as aluminum oxyhydroxide and aluminum hydroxyphosphate are commonly used human vaccine adjuvants. In an effort to improve the adjuvant activity of aluminum salts, we previously showed that the adjuvant activity of aluminum oxyhydroxide nanoparticles is significantly more potent than that of aluminum oxyhydroxide microparticles. The present study was designed to (i) understand the mechanism underlying the potent adjuvant activity of aluminum oxyhydroxide nanoparticles, relative to microparticles, and (ii) to test whether aluminum hydroxyphosphate nanoparticles have a more potent adjuvant activity than aluminum hydroxyphosphate microparticles as well. In human THP-1 myeloid cells, wild-type and NLRP3-deficient, both aluminum oxyhydroxide nanoparticles and microparticles stimulate the secretion of proinflammatory cytokine IL-1β by activating NLRP3 inflammasome, although aluminum oxyhydroxide nanoparticles are more potent than microparticles, likely related to the higher uptake of the nanoparticles by the THP-1 cells than the microparticles. Aluminum hydroxyphosphate nanoparticles also have a more potent adjuvant activity than microparticles in helping a model antigen lysozyme to stimulate specific antibody response, again likely related to their stronger ability to activate the NLRP3 inflammasome.

Indexed as

Adjuvants, ImmunologicAluminum CompoundsAnimalsAntibody FormationCell LineFemaleHumansInflammasomesInterleukin-1betaMice, Inbred BALB CMyeloid CellsNanoparticlesNLR Family, Pyrin Domain-Containing 3 ProteinAdjuvants, ImmunologicAluminum CompoundsIL1B protein, humanInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanAluminum hydroxyphosphateAluminum oxyhydroxideAntibody responseAntigen bindingIL-1βMicroparticlesNanoparticlesNLRP3 inflammasome

Identifiers

PMID27155490
PMCPMC4920416
OpenAlexW2346287469

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.